Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.
Parkinson’s disease ( PD ) is the second-most common neurodegenerative disorder that, according to DRG epidemiology, afflicts more than million people in the EU5 . Although PD treatment has been relatively stable in recent years, the treatment paradigm is complex. PD is heterogeneous, requiring individualized treatment, chronic polypharmacy, and frequent adjustments to achieve symptom control throughout a patient’s disease course. Moreover, two recent entrants (Xadago and Ongentys) have added more complexity to this largely generic market. With the treatment landscape poised to expand even further thanks to a dynamic pipeline of unique therapies designed to optimize levodopa, reduce the frequency and impact of motor response complications, or treat key nonmotor symptoms, understanding the many forces that drive EU neurologists’ clinical decision making in PD today is crucial for developers of new PD therapeutics entering an increasingly complicated market.
How does the treatment paradigm evolve as PD progresses, especially regarding motor complications and nonmotor comorbidities? What are the typical patient pathways through treatment?
What factors influence drug selection and the treatment paradigm for primary motor symptoms, motor fluctuations, and dyskinesia as the disease progresses?
Which factors drive brand use in the highly generic PD market, and how do neurologists expect their use of branded therapies to change over the next year?
Current Treatment: Provides physician insights on prescribing behavior, treatment paths, and the factors and perceptions driving brand use so that you can understand each brand’s performance and improve or defend your competitive position.